Literature DB >> 11911839

p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA.

Seong Gon Kim1, Gnana Ravi, Carsten Hoffmann, Yun Jin Jung, Min Kim, Aishe Chen, Kenneth A Jacobson.   

Abstract

A(3) adenosine receptor (A(3)AR) agonists have been reported to influence cell death and survival. The effects of an A(3)AR agonist, 1-[2-chloro-6-[[(3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-beta-D-ribofuranonamide (Cl-IB-MECA), on apoptosis in two human leukemia cell lines, HL-60 and MOLT-4, were investigated. Cl-IB-MECA (> or =30 microM) increased the apoptotic fractions, as determined using fluorescence-activated cell sorting (FACS) analysis, and activated caspase 3 and poly-ADP-ribose-polymerase. Known messengers coupled to A(3)AR (phospholipase C and intracellular calcium) did not seem to play a role in the induction of apoptosis. Neither dantrolene nor BAPTA-AM affected the Cl-IB-MECA-induced apoptosis. Cl-IB-MECA failed to activate phospholipase C in HL-60 cells, while UTP activated it through endogenous P2Y(2) receptors. Induction of apoptosis during a 48hr exposure to Cl-IB-MECA was not prevented by the A(3)AR antagonists [5-propyl-2-ethyl-4-propyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate] (MRS 1220) or N-[9-chloro-2-(2-furanyl)[1,2,4]triazolo[1,5-c]quinazolin-5-yl]benzeneacetamide (MRS 1523). Furthermore, higher concentrations of MRS 1220, which would also antagonize A(1) and A(2A) receptors, were ineffective in preventing the apoptosis. Although Cl-IB-MECA has been shown in other systems to cause apoptosis through an A(3)AR-mediated mechanism, in these cells it appeared to be an adenosine receptor-independent effect, which required prolonged incubation. In both HL-60 and MOLT-4 cells, Cl-IB-MECA induced the expression of Fas, a death receptor. This induction of Fas was not dependent upon p53, because p53 is not expressed in an active form in either HL-60 or MOLT-4 cells. Cl-IB-MECA-induced apoptosis in HL-60 cells was augmented by an agonistic Fas antibody, CH-11, and this increase was suppressed by the antagonistic anti-Fas antibody ZB-4. Therefore, Cl-IB-MECA induced apoptosis via a novel, p53-independent up-regulation of Fas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11911839      PMCID: PMC4811183          DOI: 10.1016/s0006-2952(02)00839-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  39 in total

1.  p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines.

Authors:  I Petak; D M Tillman; J A Houghton
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

2.  Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors.

Authors:  J Strickler; K A Jacobson; B T Liang
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

Review 3.  Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

Authors:  J Linden
Journal:  Trends Pharmacol Sci       Date:  1994-08       Impact factor: 14.819

4.  Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists.

Authors:  Y Yao; Y Sei; M P Abbracchio; J L Jiang; Y C Kim; K A Jacobson
Journal:  Biochem Biophys Res Commun       Date:  1997-03-17       Impact factor: 3.575

5.  Mast cell degranulation following adenosine A3 receptor activation in rats.

Authors:  J R Fozard; H J Pfannkuche; H J Schuurman
Journal:  Eur J Pharmacol       Date:  1996-03-18       Impact factor: 4.432

6.  A role for mast cells in adenosine A3 receptor-mediated hypotension in the rat.

Authors:  J P Hannon; H J Pfannkuche; J R Fozard
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

7.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.

Authors:  D Wolf; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

8.  Apoptosis by 2-chloro-2'-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells.

Authors:  D Barbieri; M P Abbracchio; S Salvioli; D Monti; A Cossarizza; S Ceruti; R Brambilla; F Cattabeni; K A Jacobson; C Franceschi
Journal:  Neurochem Int       Date:  1998 May-Jun       Impact factor: 3.921

9.  Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.

Authors:  C Friesen; I Herr; P H Krammer; K M Debatin
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  Chronic administration of adenosine A3 receptor agonist and cerebral ischemia: neuronal and glial effects.

Authors:  D K Von Lubitz; R C Lin; M Boyd; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1999-02-19       Impact factor: 4.432

View more
  17 in total

1.  A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

Authors:  M L Trincavelli; D Tuscano; M Marroni; A Falleni; V Gremigni; S Ceruti; M P Abbracchio; K A Jacobson; F Cattabeni; C Martini
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

2.  Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway.

Authors:  Mahmoud Aghaei; Mojtaba Panjehpour; Fatemeh Karami-Tehrani; Siamak Salami
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-10       Impact factor: 4.553

Review 3.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

4.  Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.

Authors:  Sarvesh Jajoo; Debashree Mukherjea; Kounosuke Watabe; Vickram Ramkumar
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

5.  Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations.

Authors:  Petr Mlejnek; Petr Dolezel; Ivo Frydrych
Journal:  J Physiol Biochem       Date:  2012-11-27       Impact factor: 4.158

6.  The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.

Authors:  Azmi Yerlikaya; Emrah Okur; Engin Ulukaya
Journal:  Tumour Biol       Date:  2012-04-04

7.  Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential.

Authors:  Jinha Yu; Seyeon Ahn; Hee Jin Kim; Moonyoung Lee; Sungjin Ahn; Jungmin Kim; Sun Hee Jin; Eunyoung Lee; Gyudong Kim; Jae Hoon Cheong; Kenneth A Jacobson; Lak Shin Jeong; Minsoo Noh
Journal:  J Med Chem       Date:  2017-08-28       Impact factor: 7.446

8.  Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors.

Authors:  Liaman K Mamedova; Bhalchandra V Joshi; Zhan-Guo Gao; Ivar von Kügelgen; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-05-01       Impact factor: 5.858

Review 9.  Adenosine receptors and cancer.

Authors:  P Fishman; S Bar-Yehuda; M Synowitz; J D Powell; K N Klotz; S Gessi; P A Borea
Journal:  Handb Exp Pharmacol       Date:  2009

Review 10.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.